Moderna, Inc.
200 Technology Square
Cambridge, MA
United States
Tel: 617-714-6500
Website: https://modernatx.com/
Email: careers@modernatx.com
About Moderna, Inc.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
mRNA is now a turning point in the history of science, medicine, technology, even humankind itself. With this breakthrough discovery, many of the world’s biggest and most challenging medical problems are no longer a question of “how?” but merely a question of “when?”
Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Stock Symbol:
MRNA
Stock Exchange:
USNASDAQ GS
Moderna employees share their thoughts on our culture, values and mission. To hear additional employee stories and learn more about our inclusive and innovative benefits offerings, visit us on our website.
1147 articles about Moderna, Inc.
-
Giuseppe Ciaramella, formerly chief scientific officer of Moderna Therapeutics’ Valera unit, has left for an unidentified stealth-mode biotech startup.
-
One can only hope that Moderna Therapeutics can live up to the hype, both scientifically and financially.
-
Moderna unleashed a torrent of updates yesterday.
-
Dr. Mendlein will be responsible for corporate strategy, product advancement and strategy, partnering and product protection.
-
Moderna to Provide Corporate and Pipeline Updates and Outline Strategic Priorities at 2018 J.P. Morgan Healthcare Conference
1/2/2018
Mr. Bancel’s presentation will take place on Monday, January 8, 2018 at 2:30 p.m. PT in Elizabethan Room C/D at The Westin St. Francis Hotel in San Francisco.
-
Moderna Publishes Preclinical Data in Cell Reports on mRNA Therapeutic to Treat Rare Liver Disease Methylmalonic Acidemia (MMA), A Disorder of Organic Acid Metabolism
12/20/2017
Moderna announced the publication of preclinical data supporting its first rare liver disease development program, an mRNA therapeutic for methylmalonic acidemia (MMA), a serious and often life-threatening organic acidemia.
-
Moderna announced that it has dosed its first patient in a Phase I trial of mRNA-4157, a mRNA-based personalized cancer vaccine.
-
Two of the top companies in the field are German-based CureVac and U.S.-based Moderna Therapeutics.
-
Moderna CEO said the company was not likely to float its initial public offering until the company has solid data on its lead mRNA treatment.
-
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
-
3 More Moderna R&D Execs Quietly Step Down
10/18/2017
So this year, Moderna has lost the head of its cancer division, its top lawyer, and its chief business officer. -
Stephen Berenson Joins Moderna’s Board Of Directors
10/10/2017
-
Moderna Announces Publication In Molecular Therapy Characterizing Potent Immune Response Generated By Its mRNA Prophylactic Vaccines
9/26/2017
-
Secretive Moderna Shakes Up R&D Model, Shows Off Early-Stage Trial Data
9/15/2017
-
Moderna Announces Pipeline And Corporate Update
9/14/2017
-
Ex-Novartis AG Exec to Lead Moderna's Manufacturing and Operations Scale-Up
8/3/2017
-
Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma
7/28/2017
-
Moncef M. Slaoui, Ph.D. Joins Moderna’s Board Of Directors
7/27/2017
-
Moderna Provides Update On mRNA Rare Disease R&D Strategy
7/27/2017
-
Publication In Cell Demonstrates Moderna’s Zika Mrna Vaccine Prevents In Utero Transmission Of Zika Virus In Mice, Protects Against Zika-Related Congenital Damage
7/13/2017